Recro Pharma

About:

Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.

Top Investors: Athyrium Capital Management LP, Broadfin Capital, Cowen Investment Management

Description:

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Total Funding Amount:

$275M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Malvern, Pennsylvania, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)recropharma.com

Founders:

Geraldine Henwood

Number of Employees:

251-500

Last Funding Date:

2023-08-24

IPO Status:

Public

Industries: